Literature DB >> 31473307

Transcription factor Fra-2 and its emerging role in matrix deposition, proliferation and inflammation in chronic lung diseases.

A Birnhuber1, V Biasin1, D Schnoegl1, L M Marsh1, G Kwapiszewska2.   

Abstract

Fos-related antigen-2 (Fra-2) belongs to the activator protein 1 (AP-1) family of transcription factors and is involved in a broad variety of cellular processes, such as proliferation or differentiation. Aberrant expression of Fra-2 or regulation can lead to severe growth defects or diverse pathologies. Elevated Fra-2 expression has been described in several chronic lung diseases, such as pulmonary fibrosis, chronic obstructive pulmonary disease and asthma. However, the pathomechanisms behind the Fra-2-induced pulmonary remodelling are still not fully elucidated. Fra-2 overexpressing mice were initially described as a model of systemic sclerosis associated organ fibrosis, with predominant alterations in the lung. High levels of Fra-2 expression give rise to profound inflammation with severe remodelling of the parenchyma and the vasculature, resulting in fibrosis and pulmonary hypertension, respectively, but also alters bronchial function. In this review we discuss the central role of Fra-2 connecting inflammation, cellular proliferation and extracellular matrix deposition underlying chronic lung diseases and what we can learn for future therapeutic options.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activator protein 1 (AP-1); Fibrosis; Pulmonary hypertension; Systemic sclerosis; Vascular remodelling

Year:  2019        PMID: 31473307     DOI: 10.1016/j.cellsig.2019.109408

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  13 in total

1.  FOSL2 deficiency delays nonalcoholic steatohepatitis progression by regulating LY6D-mediated NLRP3 activation.

Authors:  Pei-Xin Hu; Mei-Yan Sheng; Yan-Ping Liu; Chun-Qing Zhang
Journal:  Hum Cell       Date:  2022-08-05       Impact factor: 4.374

2.  Endothelin B Receptor Immunodynamics in Pulmonary Arterial Hypertension.

Authors:  Christoph Tabeling; Carla R González Calera; Jasmin Lienau; Jakob Höppner; Thomas Tschernig; Olivia Kershaw; Birgitt Gutbier; Jan Naujoks; Julia Herbert; Bastian Opitz; Achim D Gruber; Berthold Hocher; Norbert Suttorp; Harald Heidecke; Gerd-R Burmester; Gabriela Riemekasten; Elise Siegert; Wolfgang M Kuebler; Martin Witzenrath
Journal:  Front Immunol       Date:  2022-06-09       Impact factor: 8.786

3.  Mechanosensitive channel Piezo1 is required for pulmonary artery smooth muscle cell proliferation.

Authors:  Jiyuan Chen; Marisela Rodriguez; Jinrui Miao; Jing Liao; Pritesh P Jain; Manjia Zhao; Tengteng Zhao; Aleksandra Babicheva; Ziyi Wang; Sophia Parmisano; Ryan Powers; Moreen Matti; Cole Paquin; Zahra Soroureddin; John Y-J Shyy; Patricia A Thistlethwaite; Ayako Makino; Jian Wang; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2022-03-23       Impact factor: 6.011

4.  PDGFRα and αSMA mark two distinct mesenchymal cell populations involved in parenchymal and vascular remodeling in pulmonary fibrosis.

Authors:  Valentina Biasin; Slaven Crnkovic; Anita Sahu-Osen; Anna Birnhuber; Elie El Agha; Katharina Sinn; Walter Klepetko; Andrea Olschewski; Saverio Bellusci; Leigh M Marsh; Grazyna Kwapiszewska
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-02-05       Impact factor: 5.464

5.  Determining Pharmacological Mechanisms of Chinese Incompatible Herbs Fuzi and Banxia in Chronic Obstructive Pulmonary Disease: A Systems Pharmacology-Based Study.

Authors:  Kaiwen Ni; Xiaolu Cai; Yaling Chen; Linshui Zhou; Ruilin Chen; Suqun Zheng; Zhen Wang
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-31       Impact factor: 2.629

6.  Transcryptomic Analysis of Human Brain-Microvascular Endothelial Response to -Pericytes: Cell Orientation Defines Barrier Function.

Authors:  Lisa Kurmann; Michal Okoniewski; Omolara O Ogunshola; Brigitte Leeners; Bruno Imthurn; Raghvendra K Dubey
Journal:  Cells       Date:  2021-04-20       Impact factor: 6.600

7.  Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.

Authors:  Cindy Orvain; Anne Cauvet; Alexis Prudent; Christophe Guignabert; Raphaël Thuillet; Mina Ottaviani; Ly Tu; Fanny Duhalde; Carole Nicco; Frédéric Batteux; Jérôme Avouac; NingXin Wang; Michelle A Seaberg; Stacey R Dillon; Yannick Allanore
Journal:  Arthritis Res Ther       Date:  2022-01-05       Impact factor: 5.156

8.  Small Extracellular Vesicles Propagate the Inflammatory Response After Trauma.

Authors:  Tanja Seibold; Jonathan Schönfelder; Florian Weeber; André Lechel; Milena Armacki; Mareike Waldenmaier; Christoph Wille; Annette Palmer; Rebecca Halbgebauer; Ebru Karasu; Markus Huber-Lang; Miriam Kalbitz; Peter Radermacher; Stephan Paschke; Thomas Seufferlein; Tim Eiseler
Journal:  Adv Sci (Weinh)       Date:  2021-10-28       Impact factor: 16.806

Review 9.  Concepts of advanced therapeutic delivery systems for the management of remodeling and inflammation in airway diseases.

Authors:  Daljeet Singh Dhanjal; Parvarish Sharma; Meenu Mehta; Murtaza M Tambuwala; Parteek Prasher; Keshav R Paudel; Gang Liu; Shakti D Shukla; Philip M Hansbro; Dinesh Kumar Chellappan; Kamal Dua; Saurabh Satija
Journal:  Future Med Chem       Date:  2022-01-12       Impact factor: 3.808

Review 10.  Engineering Advanced In Vitro Models of Systemic Sclerosis for Drug Discovery and Development.

Authors:  Andrea De Pieri; Benjamin D Korman; Astrid Jüngel; Karin Wuertz-Kozak
Journal:  Adv Biol (Weinh)       Date:  2021-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.